August 2, 2021Journal of Clinical OncologyOpen Access

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

View Full Paper

Ask AI

Bookmark

Abstract

Amivantamab, via its novel mechanism of action, yielded robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations after progression on platinum-based chemotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Park et al. (2021) studied this question.

synapsesocial.com/papers/69dcc16189c4deb67d359857 https://doi.org/10.1200/jco.21.00662

View Full Paper

Ask AI

Bookmark

Abstract

Amivantamab, via its novel mechanism of action, yielded robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations after progression on platinum-based chemotherapy.

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Abstract

Discussion

Cite This Study

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Abstract

Discussion

Cite This Study

Also Consider

Also Consider